Importantly, MAT2A inhibitors have anti-proliferative activity in MTAP-deleted cancer cells and tumors [162], a result that prompted the development of a phase I clinical trial using MAT2A inhibitors (ClinicalTrials.gov NCT03435250) [163]. The gene discussed is MAT2A; the disease is cancer.